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Mice with targeted deletion of the GABA-degradative enzyme succinate semialdehyde dehydrogenase (SSADH; Aldh5a1; OMIM 271980)
manifest globally elevated GABA and regionally decreased arginine in brain extracts. We examined the hypothesis that arginine–glycine
amidinotransferase catalyzed the formation of guanidinobutyrate (GB) from increased GABA by quantifying guanidinoacetate (GA),
guanidinopropionate (GP) and GB in brain extracts employing stable isotope dilution gas chromatographic-mass spectrometry. GA and GB were
up to 4- and 22-fold elevated, respectively, in total and regional (cerebellum, hippocampus, cortex) brain extracts derived from SSADH−/− mice.
Corresponding analyses of urine and cerebrospinal fluid derived from SSADH-deficient patients revealed significant (Pb0.05) elevations of GA
and GB in urine, as well as GB levels in CSF. These data suggest that GB may be an additional marker of SSADH deficiency, implicate additional
pathways of pathophysiology, and identify the second instance of elevated GB in a human inborn error of metabolism.
© 2006 Elsevier B.V. All rights reserved.Keywords: Succinate semialdehyde dehydrogenase (SSADH) deficiency; Gamma-aminobutyrate (GABA); Arginine; Guanidinoacetate; Guanidinobutyrate; Creatine1. Introduction
Succinate semialdehyde dehydrogenase (SSADH) deficien-
cy (gamma-hydroxybutyric aciduria) is a rare disorder in the
catabolism of the neurotransmitter GABA [1]. In this autosomal
recessive disorder, developmental delays are prominent,
accompanied by hypotonia, ataxia, and seizures. To explore
pathophysiology, we developed a murine knockout model of
this disorder. Mice with SSADH deficiency are born at the
expected Mendelian frequency, are atactic, fail to gain weight
and succumb to lethal seizure activity before 1 month of life [1].⁎ Corresponding author. Tel.: +1 412 692 7608; fax: +1 412 692 7816.
E-mail address: michael.gibson@chp.edu (K.M. Gibson).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.01.006Disorders of creatine metabolism present with alterations in
guanidinoacetate (GA) and creatine/creatinine concentrations in
brain and physiological fluids [2]. Patients with arginine-
glycine amidinotransferase (AGAT) deficiency (OMIM
602360) manifest brain creatine deficiency and depressed
urine and plasma GA levels [3] (Fig. 1), while individuals
with guanidinoacetate methyltransferase (GAMT) deficiency
(OMIM 601240) show low creatine levels in urine and brain
accompanied by elevated GA [4]. Conversely, X-linked creatine
transporter deficiency (OMIM 300036) presents elevated
creatine in urine, associated with decreased creatine uptake in
cultured fibroblasts [5].
The structural analogue of GA, guanidinobutyrate (GB) (Fig.
2), was first isolated from mammalian brain in 1959 [6]. GB has
been detected in humans when GABA is pharmacologically
Fig. 1. Interrelationships of GABA, methionine and creatine metabolism (not all
steps are shown). Numbered enzymes include: 1, succinate semialdehyde
dehydrogenase (SSADH), site of the block in humans and mice with gamma-
hydroxybutyric aciduria; 2, arginine-glycine amidinotransferase (AGAT); and 3,
guanidinoacetate methyltransferase (GAMT). The dashed line represents the
conversion of GABA to guanidinobutyrate via the action of AGAT [17].
Upward (increased) and downward (decreased) arrows indicate dysregulated
amino acids in brain regions of SSADH−/− mice. Abbreviations: SSA, succinate
semialdehyde; GHB, gamma-hydroxybutyrate; GABA, gamma-aminobutyrate;
Gly, glycine; Arg, arginine; Orn, ornithine; SAM, S-adenosylmethionine; SAH,
S-adenosylhomocysteine; Met, methionine; Hcys, homocysteine; Ser, serine.
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previously identified in cerebrospinal fluid (CSF) derived
from patients with hyperargininemia [8] and in patients with
renal failure in whom creatinine concentrations were signifi-
cantly elevated [9]. In earlier work, we demonstrated decreased
L-arginine levels in cortex and hippocampus from SSADH−/−
mice, a disorder of GABA breakdown (Fig. 1) [10]. Since these
animals have increased brain GABA, we hypothesized that
guanidino species in brain might be altered, and specifically that
brain concentrations of GB might be raised. Accordingly, we
assessed quantities of GA, GB and guanidinopropionate (GP)
(Fig. 2) in whole and regional brain extracts derived from
SSADH−/− mice, and subsequently in physiological fluids
derived from SSADH-deficient patients. This report sum-
marizes the results of our studies.
2. Methods
Production and maintenance of the SSADH−/− mouse colony, and
quantitation of amino acids in brain regions using ninhydrin derivatization
and HPLC, has been previously reported [10]. Quantitation of GA, GP and GB
was performed using stable isotope dilution gas chromatography-mass
spectrometry, employing [13C2]GA and [
13C3
15N]GP as internal standards [11].Fig. 2. Structures of guanidinoacetate (GA), guanidiThis method uses a two step derivatization procedure which involves a reaction
with hexafluoroacetylacetone to form a bis(trifluoromethyl)pyrimidine ring
structure followed by a reaction with pentafluorobenzyl bromide. Bis
(trifluoromethyl)pyrimidine pentafluorobenzyl derivatives were separated on a
polar capillary GC-column and were quantified using negative chemical
ionisation mass fragmentography. All statistical evaluations employed a one-
tailed t test for means and standard deviations.
Physiological fluids derived from control (n=5 individuals each for CSF and
urine, not necessarily from the same individual) and those with inherited
SSADH deficiency (n=7 individuals, both urine and CSF) were obtained with
informed consent. Age and gender information were as follows: control urines
(n=5), 2 male/3 female, ages 4 yr 7 months to 8 yr 7 months; control CSF
(n=5), 3 male/2 female, ages 0 yr 8 months to 8 yr 2 months; and SSADH-
deficient patients (n=7), 5 male/2 female, ages 0 yr 11 months to 8 yr 11 months.
For seven SSADH-deficient CSF samples, two samples were obtained prior to
vigabatrin intervention, two during vigabatrin intervention, and for three the
status of vigabatrin intervention was unknown. These samples had been referred
from other diagnostic centres, and full information concerning vigabatrin dosage
(when present) was not available. As intervention with vigabatrin could lead to
artifactual elevations of GABA, total GABA determinations were performed on
CSF samples [12], with the following results: control (mean±SD; μmol/L; n=5)
7.64±2.85 (range 2.94–10.7): patients 26.64±4.85 (range 20.7–32.9; n=5)
(Pb0.0001). Assessing the values for GABA derived from these 7 patients
(prior (20.7 and 22.4 μmol/L), during (28.6 and 32.7 μmol/L) or unknown (32.9,
24.4 and 24.8 μmol/L ) status for vigabatrin intervention) using a one-way
ANOVA (non-parametric) with Kruskal–Wallis test revealed that the GABA
values were not significantly different based upon vigabatrin status (P=0.1403)
at the 95% confidence level. Similarly, using a Dunn's multiple comparison test
on the same data, PN0.05 in comparison of each group to the other. Based upon
the absence of statistical differences between the values for CSF GABA linked
to known or unknown vigabatrin status, we felt that the data for these 7 patients
could be pooled for comparison of GA and GB findings. Nonetheless, the
number of patients assessed was small, and these findings still may be
considered preliminary.3. Results
Quantities of GABA and arginine in brain regions of
SSADH+/+ and SSADH−/− (both untreated and mice pharma-
cologically rescued from early lethality [13]) have been
previously reported [10]. For all studies, at least three and up
to seven animals were employed, and control (SSADH+/+)
animals were littermates of the mutant (SSADH−/−) animals
(identical background). Total homogenates of brain frommutant
and wild-type mice revealed elevated GA and GB (SSADH+/+
(n=5mice) 24.6±1.1 (SE) and 7.9±0.3 nmol/100 mg protein;
SSADH−/− (n=3 mice) 97.2±9.9 and 168.5±7.1), respec-
tively (Fig. 3). These results were confirmed in regional (Ce—
cerebellum; Hc—hippocampus; Cx—cortex) extracts: (Ce) GA
and GB (SSADH+/+ (n=6 mice ) 31.3±1.9 and 12.5±0.3;
SSADH−/− (n=7 mice) 49.0±4.3 and 279.7±19.3); (Hc)
(SSADH+/+ (n=6 mice) 40.5±5.2 and 9.5±0.3; SSADH−/−
(n=6 mice) 62.7±7.7 and (n=7 mice) 188.9±19.1); (Cx)
(SSADH+/+ (n=6 mice) 64.2±3.6 and 11.8±0.3; SSADH−/−nopropionate (GP) and guanidinobutyrate (GB).
Fig. 3. Concentrations of guanidinoacetate and guanidinobutyrate in total brain homogenates by genotype (wild-type=SSADH+/+; mutant=SSADH−/−;
***Pb0.0001).
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(Fig. 4). Guanidinopropionate (GP; Fig. 2) was not elevated
in any of the extracts for mutant animals in comparison to
wild-type.
We followed-up mouse studies by performing corresponding
studies in control and SSADH-deficient physiological fluids
(Fig. 5). Analyses of urine samples revealed: GA (control
53.7±25.7 mmol/mol creatinine (range 20.8–77.2, n=5):
patients 85.6±29.5 (range 38.2–131.4, n=7) (Pb0.04)) and
GB (control 3.82±1.67 (range 1.98–5.77): patients 18.2±10.8
(range 4.58–34.6) (Pb0.01). Analyses of CSF samples yielded:
GA (control 0.18±0.11 μmol/L (range 0.07–0.31, n=5):
patients 0.11±0.02 (range 0.08–0.14, n=7) (P=ns)) and GB
(control 0.02±0.005 (range 0.02–0.03): patients 0.11±0.10
(range 0.04–0.32) (Pb0.03; Fig. 5).
4. Discussion
Pathophysiologically, our studies raise a number of
interesting issues with respect to SSADH deficiency. Altera-Fig. 4. Concentrations of guanidinoacetate (GA) and guanidinobutyrate (GB) in region
Cx, cortex (WT=wild type, SSADH+/+; mut=mutant, SSADH−/−; *Pb0.05; **Pbtions of arginine in SSADH−/− brain raise the potential for
disruption of the nitric oxide signaling system in this disorder.
In addition to alterations of arginine levels, amino acid
analyses in mutant mice also revealed significant disruptions
in methionine, serine, cystathionine, and taurine concentra-
tions (Fig. 1) [10], which may relate to altered GABA
metabolism via S-adenosylmethionine and S-adenosylhomo-
cysteine. This observation would be consistent with the
finding of increased GA levels in patients with combined
methylmalonic aciduria and homocystinuria (complementation
group C [cbl C]) [14]. In addition, guanidino species have
been shown to generate reactive oxygen intermediates [15],
activate GABA(A) receptors [16], and disrupt creatine
metabolism [2], raising the possibility for novel pathome-
chanisms in hereditary SSADH deficiency.
Watanabe and coworkers [17] demonstrated that AGAT
catalyzes the transamidation of the guanidino group of
arginine to ethanolamine, GABA, lysine, taurine, and several
other species. Prior to our report, the only other instances of
increased GB in humans had been described in patients withal brain extracts by genotype. Abbreviations: Ce, cerebellum; Hc, hippocampus;
0.01; ***Pb0.001).
Fig. 5. Concentrations of GA and GB in physiological fluids derived from controls and SSADH-deficient patients. Left: cerebrospinal fluid; Right: urine. All patient
samples were significantly different from control (Pb0.05) with the exception of GA in cerebrospinal fluid (P=ns).
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[9], and in urine of patients receiving vigabatrin [7]. The
finding of GB in patients receiving vigabatrin may represent
an additional unwanted side-effect of this medication, in
addition to well-described ocular manifestations [18]. Al-
though quite rare, we might expect elevated levels of GB in
patients with GABA-transaminase deficiency, although stud-
ies to confirm this possibility have not been presented [19].
At the current time, we speculate that increased GA derives
from competitive inhibition of the GAMT reaction by GB,
with resultant increase in GA. However, the fact that arginine
is low in neural tissue derived from our mice would lead us to
expect that GA would actually be decreased linked to the
AGAT reaction, which does not support our hypothesis. There
is also a remote possibility that raised GA is derived from
increased GB by the beta-oxidation spiral of fatty acid
metabolism.
To date, limited MR spectroscopy studies of SSADH-
deficient patients have not revealed alterations in creatine
levels [20], but only a few patients have been investigated
(Novotny EJ, unpublished findings). We might expect
alterations in brain creatine in our patients since guanidino
species are known to disrupt creatine metabolism, but
additional patients need to be evaluated. No spectroscopic
data for creatine are yet available on the SSADH−/− mouse
model, but these studies are in progress. Of interest, the
GAMT knockout mouse [21] manifests impaired fertility and
decreased body weight, findings consistent with SSADH−/−
mice, but does not have evidence of the epileptic activity we
have observed in SSADH−/− animals [22]. In summary, our
results suggest that SSADH deficiency represents a second
inborn error of metabolism with endogenously elevated GB,
suggesting that it may be of value to screen for GB in
conditions in which GABA is increased either through genetic
alteration or via therapeutic intervention.
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